Once More Unto the Breach, Dear Friends


I’m no Shakespearean scholar, but the rallying cry from Henry V reminded me of what it is like to find out your cancer has recurred, and that once again, you’ll be going through chemotherapy.

Last fall I noticed that my tumor markers were trending upward. My oncologist at that time wasn’t too concerned until my CA-125 reached 61 in early December 2014. At that point, I went for a PET/CT scan, and shortly after that I became symptomatic, just like I had that first time I was diagnosed in 2011. By the time January rolled around, I was miserable, and I knew the enemy had returned--its armies now attacking my liver and pelvis.

For reasons I would prefer not to go into, I decided to consult and transfer my care to another oncologist. Because of all the complications I had with my first regimen, he decided to try a different drug combination.

I swore after my first regimen that if my ovarian cancer recurred, I would never go through chemotherapy again. But there was something about this doctor’s demeanor and I found myself signing the consent forms for treatment yet once again.

The quote from Henry V is particularly apt for cancer patients, because almost no one fights cancer alone. There are friends, former coworkers, and family members who also mount the effort to beat the aberrant cells back into submission. The oncologist and his staff are also leading the charge to help this patient get back into remission. Fighting cancer is a war, and I need all hands on deck.

Will this new regimen work? I don’t know, but I’m willing to give it a try.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content